Aarkstore.com announces, The Latest market research report is available inits vast collection:Muscle Invasive Bladder Canc...
development by companies and universities/research institutes based oninformation derived from company and industry-specif...
Assessment by Monotherapy Products 18Assessment by Combination Products 19Assessment by Route of Administration 20Assessme...
B-Cell Leukemia – Pipeline Review, H2 2012Malignant Neoplasms – Pipeline Review, H2 2012Recurrent Malignant Glioma – Pipel...
Phone:08149852585Email: enquiry@aarkstore.com
Upcoming SlideShare
Loading in...5
×

Muscle invasive bladder cancer (mibc) – pipeline review, h2 2012

160

Published on

2012 || Oncology || Muscle Invasive Bladder Cancer (MIBC) – Pipeline Review, H2 2012 || Aarkstore.com

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
160
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Muscle invasive bladder cancer (mibc) – pipeline review, h2 2012

  1. 1. Aarkstore.com announces, The Latest market research report is available inits vast collection:Muscle Invasive Bladder Cancer (MIBC) – Pipeline Review, H22012http://www.aarkstore.com/reports/Muscle-Invasive-Bladder-Cancer-MIBC-Pipeline-Review-H2-2012-220602.htmlRSS link of Global Markets Directhttp://www.aarkstore.com/feeds/Global-Markets-Direct.xmlSummaryGlobal Markets Direct’s, Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review,H2 2012, provides an overview of the Muscle Invasive Bladder Cancer (MIBC)therapeutic pipeline. This report provides information on the therapeuticdevelopment for Muscle Invasive Bladder Cancer (MIBC), complete with latestupdates, and special features on late-stage and discontinued projects. It also reviewskey players involved in the therapeutic development for Muscle Invasive BladderCancer (MIBC). Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2012is built using data and information sourced from Global Markets Direct’s proprietarydatabases, Company/University websites, SEC filings, investor presentations andfeatured press releases from company/university sites and industry-specific thirdparty sources, put together by Global Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Muscle Invasive Bladder Cancer(MIBC).- A review of the Muscle Invasive Bladder Cancer (MIBC) products under
  2. 2. development by companies and universities/research institutes based oninformation derived from company and industry-specific sources.- Coverage of products based on various stages of development ranging fromdiscovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combinedtherapeutics.- Coverage of theTable of contents:List of Tables 3List of Figures 4Introduction 5Global Markets Direct Report Coverage 5Muscle Invasive Bladder Cancer (MIBC) Overview 6Therapeutics Development 7An Overview of Pipeline Products for Muscle Invasive Bladder Cancer (MIBC) 7Muscle Invasive Bladder Cancer (MIBC) Therapeutics under Development byCompanies 9Muscle Invasive Bladder Cancer (MIBC) Therapeutics under Investigation byUniversities/Institutes 10Late Stage Products 11Comparative Analysis 11Mid Clinical Stage Products 12Comparative Analysis 12Early Clinical Stage Products 13Comparative Analysis 13Pre-Clinical Stage Products 14Comparative Analysis 14Muscle Invasive Bladder Cancer (MIBC) Therapeutics – Products underDevelopment by Companies 15Muscle Invasive Bladder Cancer (MIBC) Therapeutics – Products underInvestigation by Universities/Institutes 16Companies Involved in Muscle Invasive Bladder Cancer (MIBC) TherapeuticsDevelopment 17Altor BioScience Corporation 17Muscle Invasive Bladder Cancer (MIBC) – Therapeutics Assessment 18
  3. 3. Assessment by Monotherapy Products 18Assessment by Combination Products 19Assessment by Route of Administration 20Assessment by Molecule Type 22Drug Profiles 24Gemcitabine + Cisplatin + Sunitinib - Drug Profile 24Product Description 24List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Pipeline Review, H2 2012http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H22012&PubId=&pagenum=1Cholangiocellular Hepatoma – Pipeline Review, H2 2012Hormone Refractory Breast Cancer – Pipeline Review, H2 2012Muscle Invasive Bladder Cancer (MIBC) – Pipeline Review, H2 2012Refractory Multiple Myeloma – Pipeline Review, H2 2012Epithelial Ovarian Cancer – Pipeline Review, H2 2012Neuro Endocrine (Carcinoid) Carcinoma – Pipeline Review, H2 2012
  4. 4. B-Cell Leukemia – Pipeline Review, H2 2012Malignant Neoplasms – Pipeline Review, H2 2012Recurrent Malignant Glioma – Pipeline Review, H2 2012Endobronchial Cancer – Pipeline Review, H2 2012Leiomyosarcoma – Pipeline Review, H2 2012Transitional Cell Cancer (Urothelial Cell Cancer) – Pipeline Review, H2 2012Esophageal Tumor – Pipeline Review, H2 2012Malignant Pleural Mesothelioma – Pipeline Review, H2 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcarehttp://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals andHealthcare&PubId=&pagenum=1You can also request for sample page of above mention reports onsample@aarkstore.comFor More details Plz do contact :Aarkstore EnterpriseLavanya
  5. 5. Phone:08149852585Email: enquiry@aarkstore.com

×